Amélie Dendooven

Amélie Dendooven

Auto-generated profile, based on publicly available information

Amélie Dendooven

Ghent University Hospital

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2022 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
WLWim Laurens
Wim Laurens
DDDries Deleersnijder
Dries Deleersnijder
ADAmélie Dendooven
Amélie Dendooven
ELEvelyne Lerut
Evelyne Lerut
AVAn S De Vriese
An S De Vriese
BSBen Sprangers
Ben Sprangers
Background: The Flemish Collaborative Glomerulonephritis Group (FCGG) registry is the first population-based native kidney biopsy registry in Flanders, Belgium. In this first analysis, we report on patient demographics, frequency distribution and incidence rate of biopsied kidney disease in adults in Flanders. Methods: From January 2017 to December 2019, a total of 2054 adult first native kidney biopsies were included. A ‘double diagnostic coding’ strategy was used, in which every biopsy sample received a histopathological and final clinical diagnosis. Frequency distribution and incidence rate of both diagnoses were reported and compared with other European registries. Results: The median age at biopsy was 61.1 years (interquartile range, 46.1–71.7); male patients were more prevalent (62.1%) and biopsy incidence rate was 129.3 per million persons per year. Immunoglobulin A nephropathy was the most frequently diagnosed kidney disease (355 biopsies, 17.3% of total) with a similar frequency as in previously published European registries. The frequency of tubulointerstitial nephritis (220 biopsies, 10.7%) and diabetic kidney disease (154 biopsies, 7.5%) was remarkably higher, which may be attributed to changes in disease incidence as well as biopsy practices. Discordances between histopathological and final clinical diagnoses were noted and indicate areas for improvement in diagnostic coding systems. Conclusions: The FCGG registry, with its ‘double diagnostic coding’ strategy, provides useful population-based epidemiological data on a large Western European population and allows subgroup selection for future research.

17 June 2025 in Histopathology
Verified
Journal Article
Open access
FDFrederik Deman
Frederik Deman
GBGlenn Broeckx
Glenn Broeckx
SDSabine Declercq
Sabine Declercq
QDQuentin Degotte
Quentin Degotte
JRJakob Raymaekers
Jakob Raymaekers
ADAmélie Dendooven
Amélie Dendooven
Aims: As pathology departments transition towards digital workflows, the integration of artificial intelligence (AI) is anticipated to become increasingly common. This study aimed to describe the real‐world implementation and impact of AI integration in routine pathological diagnostics, specifically focusing on prostate biopsy evaluations at the Department of Pathology, ZAS Hospitals, Antwerp.Methods and Results: An AI tool for analysing prostate biopsies was integrated into the department's daily workflow by embedding it into existing laboratory information and reporting systems. Following a short adaptation period, the use of AI led to measurable improvements. Most notably, there was a reduction in the number of immunohistochemical tests required, indicating more confident primary diagnoses. Additionally, a significant decrease in turnaround times for biopsy evaluations was observed, highlighting improved efficiency. The implementation process was closely monitored, and practical insights were gathered to guide future AI deployments in pathology.Conclusions: The first‐year experience of integrating AI into daily pathological practice demonstrated tangible benefits in diagnostic efficiency and workflow optimization. However, the process also revealed several challenges related to real‐world deployment, including adaptation by staff and system integration hurdles. The lessons learned provide valuable guidance for other institutions considering similar AI implementations, reinforcing the importance of strategic planning, training and system compatibility in successful adoption.

11 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VDValentino D’Onofrio
Valentino D’Onofrio
EDElena Donders
Elena Donders
MAMarie-Elena Vanden Abeele
Marie-Elena Vanden Abeele
JDJasperina Dubois
Jasperina Dubois
RCReinoud Cartuyvels
Reinoud Cartuyvels
JCJanneke Cox
Janneke Cox
Background: Minimally invasive autopsy (MIA) is a validated and safe method to establish the cause of death (COD), mainly in low-resource settings. However, the additional clinical value of MIA in Coronavirus disease (COVID-19) patients in a high-resource setting is unknown. The objective was to assess if and how MIA changed clinical COD and contributing diagnoses in deceased COVID-19 patients. Methods and findings: A prospective observational cohort from April to May 2020 in a 981-bed teaching hospital in the epicenter of the COVID-19 pandemic in Belgium was established. Patients who died with either PCR-confirmed or radiologically confirmed COVID-19 infection were consecutively included. MIA consisted of whole-body CT and CT-guided Tru-Cut® biopsies. Diagnostic modalities were clinical chart review, radiology, microbiology, and histopathology which were assessed by two independent experts per modality. MIA COD and contributing diagnoses were established during a multi-disciplinary meeting. Clinical COD (CCOD) and contributing diagnosis were abstracted from the discharge letter. The main outcomes were alterations in CCOD and contributing diagnoses after MIA, and the contribution of each diagnostic modality. We included 18 patients, of which 7 after intensive care unit hospitalization. MIA led to an alteration in 15/18 (83%) patients. The CCOD was altered in 5/18 (28%) patients. MIA found a new COD (1/5), a more specific COD (1/5), a less certain COD (1/5), or a contributing diagnosis to be the COD (2/5). Contributing diagnoses were altered in 14/18 (78%) patients: 9 new diagnoses, 5 diagnoses dismissed, 3 made more specific, and 2 made less certain. Overall, histopathology contributed in 14/15 (93%) patients with alterations, radiology and microbiology each in 6/15 (40%), and clinical review in 3/15 (20%). Histopathology was deemed the most important modality in 10 patients, radiology in two patients, and microbiology in one patient. Conclusion: MIA, especially histological examination, can add valuable new clinical information regarding the cause of death in COVID-19 patients, even in a high-resource setting with wide access to premortem diagnostic modalities. MIA may provide important clinical insights and should be applied in the current ongoing pandemic. Trial registration: Clinicaltrials.gov identifier: NCT04366882

24 May 2021 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
ADAmélie Dendooven
Amélie Dendooven
HPHan Peetermans
Han Peetermans
MHMark Helbert
Mark Helbert
TNTri Q. Nguyen
Tri Q. Nguyen
NMNiels Marcussen
Niels Marcussen
SLSabine Leh
Sabine Leh
Background: Kidney biopsy registries all over the world benefit research, teaching and health policy. Comparison, aggregation and exchange of data is however greatly dependent on how registration and coding of kidney biopsy diagnoses are performed. This paper gives an overview over kidney biopsy registries, explores how these registries code kidney disease and identifies needs for improvement of coding practice. Methods: A literature search was undertaken to identify biopsy registries for medical kidney diseases. These data were supplemented with information from personal contacts and from registry websites. A questionnaire was sent to all identified registries, investigating age of registries, scope, method of coding, possible mapping to international terminologies as well as self-reported problems and suggestions for improvement. Results: Sixteen regional or national kidney biopsy registries were identified, of which 11 were older than 10 years. Most registries were located either in Europe (10/16) or in Asia (4/16). Registries most often use a proprietary coding system (12/16). Only a few of these coding systems were mapped to SNOMED CT (1), older SNOMED versions (2) or ERA-EDTA PRD (3). Lack of maintenance and updates of the coding system was the most commonly reported problem. Conclusions: There were large gaps in the global coverage of kidney biopsy registries. Limited use of international coding systems among existing registries hampers interoperability and exchange of data. The study underlines that the use of a common and uniform coding system is necessary to fully realize the potential of kidney biopsy registries.

31 July 2023 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
KLKan Yan Chloe Li
Kan Yan Chloe Li
HDHector Dejea
Hector Dejea
KWKoen De Winne
Koen De Winne
ABAnne Bonnin
Anne Bonnin
VDValentino D'Onofrio
Valentino D'Onofrio
ADAmélie Dendooven
Amélie Dendooven

29 August 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AWAnnick De Weerdt
Annick De Weerdt
ADAmélie Dendooven
Amélie Dendooven
ASAnnemie Snoeckx
Annemie Snoeckx
JPJan Pen
Jan Pen
MLMartin Lammens
Martin Lammens
PJPhilippe G. Jorens
Philippe G. Jorens
The FOLFOX regimen, i.e., folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that is used to treat gastric and colorectal cancers. Despite the concomitant improvements in response rate, duration of response and patient survival, reports of serious toxic pulmonary side effects have progressively emerged. We describe a patient who was treated with FOLFOX as an adjuvant to a rectosigmoidal resection of a rectosigmoidal carcinoma and who developed respiratory insufficiency requiring mechanical ventilation. Computed tomography (CT) imaging and open lung biopsy findings were compatible with interstitial pneumonia (IP). She received multimodal combination treatment (acetylcysteine, corticosteroids, immune globulins and cyclophosphamide) and survived. We performed a systematic literature search and reviewed all 45 reported cases of FOLFOX-related lung toxicity and/or pulmonary fibrosis for their clinical characteristics and their outcomes related to therapy. We found that for the 45 cases with available data, the median age was 70 years, and the male–female ratio was 3.5: 1. In the patients exhibiting only mild respiratory symptoms, discontinuation of the culprit drug (oxaliplatin) resulted in a 100% regression of the symptoms. However the prognosis of the respiratory insufficient patient proved to be grim: death occurred in 76.9% of the cases despite conventional treatment with corticosteroids. We therefore urge oncologists and critical care specialists not to limit their interventions to the discontinuation of chemotherapy, artificial ventilation, corticosteroids and glutathione replenishment and to consider the gradual introduction of additional immune-modulating agents whenever life-threatening respiratory symptoms in oxaliplatin-treated patients do not subside; all the more so considering the fact that our analysis showed that every patient who survived intubation and mechanical ventilation experienced a full clinical recovery.